Billing Laboratory Tests Without LCDs: How Labs Stay Profitable Despite Coverage Gaps

A test is ordered. The sample arrives. Your team processes it correctly. The claim goes out on time. And then it comes back denied — not because anything was done wrong, but because there is no Local Coverage Determination governing that code, and the payer had no framework for evaluating whether it should pay.

If that scenario is familiar, you are dealing with one of the most underappreciated revenue challenges in laboratory billing: the non-covered test. Not a dirty claim. Not a coding error. Just a test that sits outside the formal coverage structure that Medicare and most commercial payers rely on to make payment decisions.

 

This article explains why tests without LCDs require a fundamentally different billing approach, what that approach looks like in practice, and how a properly structured billing operation turns coverage gaps into managed revenue — rather than recurring write-offs.

 

What It Means to Bill Without an LCD

 

A Local Coverage Determination is a policy issued by a Medicare Administrative Contractor that defines whether a specific service is covered in that jurisdiction, under what clinical circumstances, and with what documentation attached. When an LCD exists for a CPT code, the billing rules are explicit: meet the criteria and you get paid; miss them and you get denied.

 

When no LCD exists for a test, those rules are absent. The MAC has made no determination about coverage. That absence does not mean the test is automatically covered — it means the payer has no standing policy to apply, which creates an indeterminate billing environment that most billing systems are not designed to navigate.

 

New molecular diagnostics, emerging genetic panels, novel toxicology assays, and certain specialty tests often enter the market before coverage policy catches up. Labs performing these tests face a billing landscape where the standard playbook does not apply. Submitting claims with the same workflow used for LCD-governed codes generates denials. Doing nothing generates no revenue. The labs that stay profitable are the ones with a third option: a structured non-covered billing protocol.

 

The Three Paths When No LCD Applies

 

When a test has no governing LCD, labs generally have three options. Each has financial and compliance implications, and the right choice depends on the payer, the clinical context, and the lab's documentation infrastructure.

 

1. Bill With Medical Necessity Documentation and Accept Adjudication

 

Some MACs will pay claims for non-covered tests if the submission includes robust medical necessity documentation and an appropriate diagnosis code linking the test to a specific clinical indication. This path requires the ordering provider to supply detailed clinical notes supporting why the test was necessary — not just that it was ordered, but why it was clinically indicated for that patient.

 

The risk here is inconsistency. Without an LCD, payer adjudication decisions are made case by case, often by reviewers without deep clinical expertise in the test in question. Payment rates for this pathway tend to be lower and less predictable than for LCD-governed tests. Labs taking this approach need to track adjudication patterns by payer and MAC jurisdiction to understand where it works and where it does not.

 

2. Issue an Advance Beneficiary Notice and Bill the Patient

 

When Medicare coverage is uncertain or unlikely, labs can issue an Advance Beneficiary Notice of Noncoverage before performing the test. A valid ABN notifies the patient that Medicare may not pay and obtains their written acknowledgment that they accept financial responsibility if Medicare denies.

 

This path only works if the ABN is issued before the test is performed. An ABN issued after the fact is invalid and provides no protection. It also requires that the billing system can identify non-covered tests before the order is processed — not after the claim has already been submitted and denied. For labs with high volumes of emerging diagnostic tests, ABN workflow automation is not optional. It is the difference between capturing revenue and writing it off.

 

3. Pursue Payer-Specific Agreements or Coverage Exceptions

 

Commercial payers handle non-covered tests differently from Medicare. Some have their own coverage policies that extend to codes with no LCD equivalent. Others will negotiate test-specific coverage agreements with labs performing high volumes of a particular assay. For specialty diagnostics with strong clinical evidence but no formal coverage determination, labs should pursue direct payer engagement — submitting clinical evidence packages, requesting coverage reviews, or negotiating single-case agreements for high-cost tests.

 

This path is more resource-intensive but can establish a payment precedent that converts a non-covered test into a consistently reimbursable one. Labs with dedicated managed care contracting teams are better positioned here than those relying entirely on their billing vendor for payer relationship management.

 

Why Standard Billing Systems Fail on Non-Covered Tests

 

Most laboratory billing platforms are designed around tests that have coverage policy. They apply diagnosis codes, validate LCD criteria, check eligibility, and submit claims. That workflow works well for the portion of a lab's test menu with formal coverage determinations. It does not work for tests with no LCD governing them.

 

A general billing system presented with a CPT code that has no LCD mapping will either pass the claim through without coverage validation — generating an inevitable denial — or flag it as unbillable because it cannot classify the coverage status. Neither outcome is acceptable at scale. Labs processing thousands of claims per month cannot afford to have non-covered tests cycle through the same workflow as covered tests and accumulate denials before anyone identifies the pattern.

 

The structural failure is in the test-level logic. A billing system that cannot distinguish between a covered test with an LCD, a covered test without an LCD that may still pay with documentation, and a non-covered test that requires an ABN before the sample is even collected is not equipped for the current diagnostic testing environment. New test codes are added to CPT every year. Coverage policy consistently lags behind clinical adoption. The gap between what labs bill and what payers have formal policies for is widening, not closing.

 

This is one of the key reasons why the choice between general RCM tools and specialty-specific laboratory billing platforms matters so much for labs with active new test menus. The infrastructure differences between the two show up most acutely on non-LCD tests, precisely because that is where the absence of built-in specialty logic is most consequential.

 

What a Properly Built Non-LCD Billing Protocol Looks Like

 

Labs that successfully capture revenue from non-covered tests share a set of operational practices that go beyond the claims submission workflow. These practices are built upstream, at the point where an order is received, not downstream after a denial arrives.

 

1. Test classification at the order level. Every CPT code in the lab's test menu should be tagged by coverage status — LCD-covered, potentially payable without LCD, likely non-covered, or payer-dependent. That classification drives the workflow: what documentation is required before the claim goes out, whether an ABN is needed before the test is performed, and which billing path applies for each payer.
2. Pre-test eligibility and coverage screening. For tests without LCDs, eligibility verification must do more than confirm that the patient has active coverage. It must assess whether that coverage has any policy governing the test in question and flag the claim for enhanced documentation or ABN issuance before the sample is collected. This requires a billing system capable of payer-specific coverage logic at the test level, not just a generic eligibility check.
3. ABN automation integrated with the order workflow. ABN generation cannot be a manual step that depends on a billing team member catching a non-covered test after the order is placed. It needs to be triggered automatically when the order entry system identifies a code with uncertain or absent LCD coverage. The patient notification must happen before the service is performed, or the ABN is invalid.
4. Clinical documentation templates by test type. For tests that may pay without an LCD if medical necessity is established, labs should work with their ordering providers to standardize the clinical documentation that accompanies those claims. A reusable documentation template linked to specific CPT codes reduces the variability in what providers submit and increases the consistency of adjudication outcomes.
5. Adjudication tracking by payer, code, and MAC jurisdiction. Non-covered test billing generates payment data that should inform future billing decisions. Which payers pay for which tests with what documentation? Which MAC jurisdictions have informal local coverage policies that are not published as formal LCDs but consistently produce payment? That institutional knowledge needs to be captured in the billing system and updated as adjudication patterns evolve.
6. Appeals infrastructure for systematic denials. Labs billing non-covered tests should expect a higher denial rate than on LCD-governed claims and should have a defined appeals workflow for each denial type. A denial on a non-covered test is not necessarily final. With the right clinical documentation attached to an appeal, some percentage of those denials convert to payment. Labs that do not have a systematic appeals process are leaving a meaningful portion of that revenue on the table.

 

The Connection Between Non-LCD Tests and Broader Compliance Risk

 

Non-covered test billing carries compliance exposure that goes beyond the immediate revenue impact. Labs that bill tests without LCDs using the same workflow as covered tests, without proper ABN documentation or medical necessity support, can generate a claims pattern that looks indistinguishable from systematic overbilling to a payer auditor.

 

The Office of Inspector General has consistently identified laboratory billing as a high-priority audit focus, with particular attention to labs submitting high volumes of claims for tests that lack adequate medical necessity documentation. A non-covered test submitted without appropriate documentation is not just a denied claim. Depending on the pattern and volume, it can be construed as a false claim under federal audit standards.

 

The compliance protection for non-covered test billing comes from the same place as the revenue protection: a documented process that was applied consistently before the claim was submitted. ABN records, medical necessity documentation, payer-specific coverage screens, and adjudication tracking are not just billing tools. They are audit documentation. Labs that can produce a clear paper trail showing that non-covered tests were identified, patients were notified, and claims were submitted with appropriate supporting documentation are in a fundamentally different position than labs that cannot.

 

That level of documentation does not happen by accident in a high-volume lab. It requires a billing infrastructure that was designed to produce it at scale, consistently, across every test in a potentially non-covered category.

 

How ADS Supports Labs Billing Outside Traditional Coverage Frameworks

 

ADS has supported laboratory billing operations with specialty-specific infrastructure since 1977. That includes the full scope of LCD and NCD compliance for covered tests — and equally, the non-covered test protocols that keep labs profitable when formal coverage policy has not yet caught up to their test menu.

 

The ADSRCM platform maintains test-level coverage classification across CPT codes, supports automated ABN workflows triggered at the order level, and tracks adjudication patterns by payer and MAC jurisdiction to build institutional knowledge about what pays and what does not for tests in coverage gray zones. The result is a billing operation that treats non-covered tests as a managed revenue category rather than a recurring write-off category.

 

Labs evaluating their current billing infrastructure can see how the ADSRCM approach applies to their specific test menu and payer mix. The laboratory billing software and services overview covers the full platform, and the team is reachable directly to walk through non-covered test scenarios specific to your lab's specialty and volume.

 

Ready to see what 49 years of specialty-specific laboratory billing looks like in practice?

 

Request a Live Demonstration and see how ADSRCM applies non-LCD billing logic to your actual test menu and payer mix. Call 1-800-899-4237 ext. 2264 — a real person answers in under two minutes.

 

Sources

 

CMS Medicare Coverage Database (cms.gov/medicare/coverage) | College of American Pathologists (cap.org) | AACC (aacc.org) | OIG Work Plan (oig.hhs.gov) | Advanced Data Systems Corporation (adsc.com)